Neoadjuvant chemotherapy in patients with advanced endometrial cancer
ConclusionsUnlike ovarian cancer, less than half of the patients undergoing NACT for endometrial cancer underwent IDS, none had a complete response, and 41% had disease progression during NACT. However, endometrial cancer patients who underwent IDS had a high rate of optimal cytoreduction. Both response to NACT and IDS were associated with improved survival.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Carcinosarcoma | Chemotherapy | Drugs & Pharmacology | Endometrial Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Neurology | Neurosurgery | Ovarian Cancer | Ovaries | Study